Management of INR 1.35 in a Warfarin Patient Without Bleeding
An INR of 1.35 is subtherapeutic and requires warfarin dose adjustment to achieve the target therapeutic range of 2.0-3.0, with more frequent INR monitoring until stability is achieved. 1, 2
Understanding the Clinical Context
Your patient's INR of 1.35 falls well below the therapeutic range of 2.0-3.0 recommended for most indications including atrial fibrillation, venous thromboembolism, and mechanical heart valves. 1, 2 This subtherapeutic anticoagulation places the patient at increased risk for thromboembolic events including stroke, particularly in high-risk conditions like atrial fibrillation where warfarin reduces stroke risk by 60-86% when properly dosed. 1
Immediate Management Steps
Dose Adjustment Strategy
Increase the total weekly warfarin dose by 10-20% rather than making dramatic single-dose changes. 3 For example, if the patient takes 5 mg daily (35 mg/week), increase to approximately 38.5-42 mg weekly, distributed across the week.
Avoid loading doses as these can cause excessive INR elevation and do not provide immediate anticoagulation benefit given warfarin's mechanism of action. 3
The anticoagulant effect persists beyond 24 hours, so dose adjustments will not show immediate INR changes. 2
INR Monitoring Frequency
Check INR 2-4 times per week until the therapeutic range (2.0-3.0) is achieved and stable. 1, 3 This is critical because subtherapeutic INRs require close monitoring during dose titration.
Once stable in therapeutic range, gradually extend monitoring intervals up to a maximum of 4 weeks. 1, 2
Investigating the Cause of Subtherapeutic INR
Before simply increasing the dose, identify why the INR dropped:
Medication adherence: Missed doses are common. 2 Ask specifically about the last 7 days of dosing.
New medications: Many drugs decrease warfarin effect (vitamin K-containing supplements, rifampin, carbamazepine, phenytoin, etc.). 2
Dietary changes: Increased vitamin K intake from green leafy vegetables can lower INR. 2
Warfarin resistance: Rare but should be suspected if large doses are required to maintain therapeutic INR. 2
Risk Stratification During Subtherapeutic Period
The patient remains at elevated thromboembolic risk until therapeutic INR is restored. 1
For atrial fibrillation patients, assess CHA₂DS₂-VASc score to quantify baseline stroke risk. 1 Higher scores indicate greater urgency in achieving therapeutic anticoagulation.
Consider bridging therapy with low-molecular-weight heparin (LMWH) only in very high-risk patients (e.g., recent stroke/TIA, mechanical mitral valve, recent VTE), though this is not routinely indicated for mildly subtherapeutic INRs without acute thrombotic events. 1
Common Pitfalls to Avoid
Do not make dose adjustments based on a single slightly out-of-range INR if the patient has been previously stable—but 1.35 is significantly subtherapeutic and warrants action. 3
Do not double the next dose to "catch up"—this creates unpredictable anticoagulation. 2
Do not assume the patient will spontaneously return to therapeutic range without intervention—investigate and adjust. 3
Alternative Anticoagulation Consideration
If the patient cannot maintain therapeutic INR despite appropriate dosing and adherence, consider switching to a direct oral anticoagulant (DOAC) such as apixaban, rivaroxaban, or dabigatran for nonvalvular atrial fibrillation. 1 This recommendation is particularly relevant given that patients in usual care maintain therapeutic INR only 33-64% of the time with warfarin. 2